MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:44Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:H1 receptor antagonists]]
			[[Category:Mast cell stabilizers]]
			[[Category:Intranasal antihistamines]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #142

2026-05-23T04:19:17Z

parser-claude batch MedTemplate pre-fill, Top 300 #142

New page

{{MedTemplate
| generic = Azelastine
| brand = Astelin, Astepro (intranasal); Optivar (ophthalmic); with fluticasone as Dymista
| structure =
| classes = [[:Category:H1_receptor_antagonists|Histamine H1 receptor antagonist]], [[:Category:Mast_cell_stabilizers|Mast cell stabilizer]], [[:Category:Intranasal_antihistamines|Intranasal antihistamine]]
| uses = <vote slug="allergic-rhinitis-use">Allergic rhinitis (intranasal)</vote>, <vote slug="vasomotor-rhinitis-use">Vasomotor rhinitis (intranasal)</vote>, <vote slug="allergic-conjunctivitis-use">Allergic conjunctivitis (ophthalmic)</vote>
| starting_dose = Intranasal 0.1% or 0.15%: 1-2 sprays/nostril BID; ophthalmic 0.05%: 1 drop in each eye BID
| preparations = 0.1%, 0.15% intranasal spray; 0.05% ophthalmic solution; combination Dymista (azelastine 0.137 mg + fluticasone 50 mcg/spray)
| fda_max = 2 sprays/nostril BID
| pill_id =
| routes = Intranasal, topical ophthalmic
| onset = 15 minutes
| duration = 12 hours
| halflife = ~22 hours; longer 54 hours (desmethylazelastine, active metabolite)<ref name="astepro-label">FDA Prescribing Information, Astepro (azelastine HCl) nasal spray, Bayer (now OTC), current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021488s016lbl.pdf</ref>
| bioavailability = Intranasal ~40% systemic; ophthalmic minimal<ref name="astepro-label" />
| pregnancy = Limited data; second-line to intranasal corticosteroids or PO loratadine/cetirizine.{{citation needed}}
| legal = OTC (Astepro 0.15%) and [[USLegal:Prescription only|Rx-only]] (other intranasal, ophthalmic, Dymista) in US
| mechanism = <vote slug="azelastine-mech-claim">Azelastine is a phthalazinone H1 receptor antagonist with mast cell stabilizing activity; the dual mechanism provides faster nasal symptom relief than intranasal corticosteroids alone in allergic rhinitis.</vote> Topical application minimizes systemic antihistaminic burden; the characteristic bitter taste with nasal use (drainage to oropharynx) is the main tolerability issue<ref name="astepro-label" />.
}}

== References ==
<references />

Azelastine - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #142